The molecular diagnostics market, in which Cepheid (NASDAQ:CPHD) is a prominent player, is expected to grow rapidly at a 42% CAGR through 2017. Currently CPHD is trading at a multi-year high due to the immense industry growth prospects.
CPHD data by YCharts
CPHD has a broad range of tests that runs on its GeneXpert systems across infectious diseases, hospital acquired infections ("HAI"), women's health, genetics and oncology. I believe that two recent developments can drive the company's stock ~25% higher from the current level around $47. This article will focus on these developments.
Growth Opportunities from TB Detection
A few months ago the FDA approved Cepheid to market its Xpert MTB/RIF assay in the U.S. It's going to...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|